Squamous Cell Carcinoma (2026): Types, Symptoms, Diagnosis and Treatment

Written by: Shifam Health Editorial Team — Oncology Content Division Medically reviewed by: Shifam Health Clinical Advisory Panel Published: January 2026 | Last updated: January 2026 Sources: National Cancer Institute, NCCN Guidelines, ESMO Clinical Practice Guidelines, ASCO, American Cancer Society, AJCC Cancer Staging Manual, peer-reviewed oncology literature

Squamous cell carcinoma (SCC) is a malignant tumor arising from squamous cells — the flat, scale-like epithelial cells that cover the outer surface of the skin and line many internal organ surfaces. Squamous cells are part of the normal lining of the skin, mouth, throat, cervix, oesophagus, anus, vulva, and other structures. When these cells undergo malignant transformation, the resulting cancer is classified as squamous cell carcinoma regardless of which organ it originates from.

SCC is one of the most common cancer types globally. In dermatology, it is the second most common skin cancer after basal cell carcinoma. In many other specialties, SCC represents a major histological cancer subtype. The behaviour, treatment, and outcome of SCC differ profoundly depending on where in the body it originates — which is the central point this guide is designed to clarify.

SCC Is Not One Disease — Why Anatomical Origin Matters

“Squamous cell carcinoma” is a histological classification — a description of the cell type not a single disease with one treatment. Skin SCC and cervical SCC share a cell type but are completely different cancers, managed by different specialists under different staging systems with different treatments.

This distinction matters enormously for patients. Someone diagnosed with cutaneous SCC of the hand has a very different prognosis and treatment pathway from someone diagnosed with squamous cell carcinoma of the lung or oesophagus. Using one survival figure or one treatment description for “SCC” would be medically misleading.

SCC at a Glance — By Anatomical Site

Cutaneous Squamous Cell Carcinoma (Skin SCC)

Cutaneous SCC is the most commonly searched form of squamous cell carcinoma and the second most common skin cancer overall. It arises from the squamous keratinocytes of the epidermis — the outer layer of the skin — and most commonly develops on sun-exposed areas. The majority of cutaneous SCCs are localised and effectively treated, though a minority develop high-risk features and can spread to lymph nodes or distant sites.

Where Skin SCC Typically Develops

• Face, lips, and ears
• Scalp
• Neck
• Back of the hands and forearms
• Lower legs (particularly in women)
• Genitalia (Bowen’s disease, erythroplasia of Queyrat)
• Within chronic wounds, scars, or areas of prior radiation

SCC can also develop on mucous membranes of the mouth and lower lip — this represents the transition between cutaneous and mucosal disease.

What Skin SCC Looks Like

SCC has no single universal appearance. Possible presentations include:

• A firm, rough, or scaly pink/red patch that doesn’t resolve
• A raised, crusted nodule
• A wart-like growth
• A non-healing sore or ulcer, sometimes with raised edges
• A lesion that bleeds repeatedly with minor trauma
• A tender or painful skin lesion
• A flat lesion that is brownish, skin-coloured, or red

The key clinical concern is a lesion that doesn’t heal, grows progressively, or changes in character. Appearance alone cannot confirm SCC — tissue biopsy is required.

High-Risk Features in Cutaneous SCC

Not all skin SCCs behave the same way. Features associated with higher risk of recurrence or regional spread include:

• Size greater than 2 cm (or 1 cm in high-risk locations such as the face/ears)
• Depth of invasion beyond certain thresholds
• Poor differentiation — more aggressive tumor cells under the microscope
• Perineural invasion — tumor cells growing along nerve sheaths
• Lymphovascular invasion
• Location in high-risk areas (ear, central face, lip, scalp, genitalia)
• Immunosuppression (organ transplant recipients, patients on immunosuppressive therapy, HIV)
• Recurrent tumor — SCC recurring after previous treatment
• Arising in a scar, chronic wound, or prior radiation field
• Invasion of bone, cartilage, or deep structures

These features influence the choice of treatment (particularly the indication for Mohs surgery) and the need for lymph-node assessment.

Actinic Keratosis and Its Relationship to Skin SCC

Actinic keratosis (AK) is a common precancerous keratinocytic lesion caused by chronic sun damage. Some actinic keratoses progress to invasive squamous cell carcinoma — but many do not, and not every actinic keratosis requires the same urgency as a confirmed SCC.

What Actinic Keratosis Is

Actinic keratoses are rough, scaly patches on sun-damaged skin, most often appearing on the face, scalp, ears, neck, forearms, and hands of older adults with significant cumulative sun exposure. Histologically, they represent intraepidermal keratinocytic atypia — the precursor state before invasive cancer develops.

The Progression Question

Studies consistently show that the individual annual risk of any single actinic keratosis progressing to invasive SCC is low. However, patients with many actinic keratoses, particularly those with immunosuppression, have a higher cumulative risk over time. This is why management of the “field” of photodamaged skin — not just individual lesions — is important for high-risk patients.

Treatment of Actinic Keratosis

Treatment options include cryotherapy, topical therapies (fluorouracil, imiquimod, diclofenac, ingenol mebutate), photodynamic therapy, and laser treatments, depending on the number, location, and severity of lesions. The goal is to reduce the burden of precancerous disease. Treating an actinic keratosis is not the same as treating invasive SCC, and patients should not assume that having their AKs treated eliminates future cancer risk.

Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) encompasses a group of cancers arising from the squamous epithelium of the oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx. These are clinically distinct entities with different risk factors, staging, and treatment approaches — and they should not be grouped as a single disease.

Common Sites and Their Distinct Features

Oral cavity SCC (lips, tongue, floor of mouth, gums, hard palate, buccal mucosa): Strongly associated with tobacco and alcohol; surgery is often the primary treatment in resectable disease.

Oropharyngeal SCC (soft palate, tonsils, base of tongue, posterior pharyngeal wall): Split into HPV-positive and HPV-negative disease — see Section 6. HPV-positive disease has a substantially different prognosis and may have different treatment sensitivity.

Laryngeal SCC (glottic, supraglottic, subglottic): Strongly associated with tobacco and alcohol; treatment aims to preserve voice function where possible; options include surgery, radiation, or concurrent chemoradiation.

Hypopharyngeal SCC: Often presents at advanced stage; associated with poor prognosis; multimodal treatment is typically required.

Multidisciplinary Management

Head and neck SCC invariably requires multidisciplinary assessment. A team including head and neck surgery, medical oncology, radiation oncology, speech and swallowing therapy, dentistry, and nutrition should be involved before treatment decisions are made.

HPV-Associated SCC — A Biologically Distinct Group

Human papillomavirus (HPV) — particularly high-risk strains, most commonly HPV-16 — is causally linked to squamous cell carcinomas arising in the oropharynx, cervix, anus, vulva, and penis. HPV-positive oropharyngeal SCC is now recognised as a biologically distinct entity from tobacco-associated HPV-negative oropharyngeal SCC, with different epidemiology, staging, prognosis, and increasingly differentiated treatment approaches.

Where HPV Is Most Clinically Relevant in SCC

HPV-Positive vs HPV-Negative Oropharyngeal SCC

Important: HPV-positive oropharyngeal SCC still requires treatment. The more favourable biology does not mean the cancer can be ignored — it means ongoing research is examining whether selected patients can achieve the same outcomes with less intensive treatment.

HPV Vaccination and Prevention

HPV vaccination (e.g., Gardasil 9) is effective against the high-risk HPV strains most associated with HPV-related cancers. Current guidance supports vaccination in adolescents and selected adults in many countries. Vaccination does not treat existing HPV infection but reduces the risk of future infection with covered strains.

Cervical Squamous Cell Carcinoma

Direct answer: Squamous cell carcinoma accounts for approximately 70–80% of all cervical cancers. Persistent infection with high-risk HPV — most commonly HPV-16 and HPV-18 — is the necessary cause of nearly all cervical SCC. Cervical screening programmes (cytology and HPV testing) can detect precancerous changes (CIN — cervical intraepithelial neoplasia) before invasive cancer develops.

Important Distinctions from Other SCCs

Cervical SCC is staged using the FIGO (International Federation of Gynaecology and Obstetrics) staging system — not the head-and-neck or skin staging frameworks. It is managed by gynecologic oncologists, not dermatologists or head and neck surgeons. Treatment is completely different from other SCC types: chemoradiation (concurrent cisplatin with radiation) is the primary treatment for most locally advanced cervical cancers.

Treatment Overview

• Early/localised disease: Surgery (in eligible patients) or definitive radiotherapy
• Locally advanced disease: Concurrent chemoradiation followed by brachytherapy (internal radiation) is the standard of care
• Recurrent/metastatic disease: Systemic therapy including chemotherapy combinations and immunotherapy (pembrolizumab has regulatory approval in certain settings) — verify current 2026 guideline status

Cervical cancer is one of the most preventable cancers given the availability of HPV vaccination and effective screening programmes.

Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma (ESCC) is one of two major histological types of oesophageal cancer (the other being adenocarcinoma). It arises from the squamous epithelium lining the upper and middle oesophagus and has a strong global association with tobacco smoking, alcohol consumption, and hot beverage consumption in certain populations and regions.

Key Features

• More common in certain Asian, African, and Central Asian populations than in Western countries
• Typically located in the upper two-thirds of the oesophagus
• Often presents at advanced stage because of the oesophagus’s anatomical position and the absence of early symptoms
• Treatment depends heavily on disease stage and the patient’s functional status

Treatment Overview

• Very early (superficial) lesions: Endoscopic resection at experienced centres
• Localised, operable disease: Surgery (oesophagectomy) ± perioperative chemotherapy or chemoradiation
• Locally advanced disease: Definitive chemoradiation (for selected patients who are not surgical candidates or as neoadjuvant therapy)
• Advanced/metastatic disease: Systemic treatment — chemotherapy, immunotherapy; verify current 2026 first-line options including checkpoint inhibitors in appropriate settings

Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma is a major subtype of non-small cell lung cancer (NSCLC), accounting for approximately 25–30% of all lung cancers. It arises from the squamous epithelium of the bronchi (airways) and is strongly associated with tobacco smoking. It is not the same as small cell lung cancer (SCLC), which has a very different biology and treatment.

Key Distinguishing Features

• Located in the central airways (bronchi) in most cases — rather than the lung periphery where adenocarcinoma tends to occur
• Strongly associated with smoking; less common in never-smokers compared with adenocarcinoma
• Molecular testing (EGFR, ALK, ROS1, KRAS, and others) is still performed, though targetable driver mutations are less common in squamous histology than in adenocarcinoma; PD-L1 testing is important for immunotherapy eligibility
• Staging uses the lung cancer AJCC TNM staging system

Treatment Overview

• Early stage (I–II): Surgery (lobectomy or limited resection at appropriate stage) ± adjuvant treatment
• Locally advanced (Stage III): Concurrent chemoradiation ± consolidation immunotherapy in selected patients
• Advanced/metastatic: Immunotherapy (pembrolizumab and others, depending on PD-L1 and whether chemotherapy combination is used), chemotherapy; targeted therapy is less commonly applicable than in adenocarcinoma but biomarker testing should still be performed

Anal, Vulvar, and Penile SCC

Squamous cell carcinomas of the anus, vulva, and penis share HPV as an important causal factor for a significant proportion of cases, though HPV-independent pathways also exist for vulvar and penile SCC. Each is managed by different specialists and requires site-specific treatment planning.

Anal Squamous Cell Carcinoma

Chemoradiation — typically concurrent 5-fluorouracil and mitomycin-C (or cisplatin) with radiation — is the established primary treatment for most localised anal SCC and can achieve good local control without requiring surgery in many cases. Surgery (abdominoperineal resection) is generally reserved for persistent or recurrent disease after chemoradiation. Advanced/metastatic disease requires systemic therapy; immunotherapy (pembrolizumab) has regulatory approval in certain MSI-H or refractory settings.

Vulvar SCC

Surgery is central to the management of most vulvar SCC. Sentinel lymph node biopsy has replaced routine inguinal lymph-node dissection in appropriately selected early-stage cases, reducing morbidity. Radiation and chemoradiation may be used for locally advanced or unresectable disease, and for postoperative adjuvant treatment in high-risk cases.

Penile SCC

Early-stage penile SCC may be managed with organ-preserving approaches (topical therapy, glans-sparing surgery, laser, radiation) when technically feasible. More locally advanced tumors require partial or total penectomy. Inguinal lymph-node assessment (sentinel node biopsy or modified lymph-node dissection based on risk stratification) is important because lymph-node involvement significantly affects prognosis.

Causes and Risk Factors by Site

SCC risk factors differ significantly by anatomical location — UV radiation is central to cutaneous SCC, while HPV, tobacco, and alcohol are the main drivers for mucosal SCCs at different sites. Most patients have some identifiable risk factors, but their presence does not make cancer inevitable.

Cutaneous SCC Risk Factors

Mucosal SCC Risk Factors

Symptoms — Organised by Anatomical Location

Because squamous cell carcinoma can arise in many different organs, symptoms vary dramatically by site. The common thread across all SCC types is a lesion or symptom that persists, progresses, or fails to heal — but the specific presentation is entirely location-dependent.

Skin SCC

• Persistent rough, scaly, or red patch that doesn’t resolve over weeks
• Non-healing sore or ulcer with or without raised edges
• Crusted or keratotic (hard) bump
• A wart-like growth, especially if it grows or changes
• A lesion that repeatedly bleeds with minimal trauma
• Tender or painful skin lesion

Head and Neck SCC

• Persistent sore or ulcer in the mouth, on the tongue, or at the back of the throat
• Neck lump (swollen lymph node) that persists for more than 2–3 weeks
• Difficulty swallowing or painful swallowing
• Persistent hoarseness or voice change
• Persistent sore throat not explained by infection
• Referred ear pain (otalgia) without obvious ear pathology
• Bleeding from the mouth or throat
• Unexplained weight loss

Cervical SCC

• Abnormal vaginal bleeding — between periods, after intercourse, or postmenopausally
• Unusual or offensive vaginal discharge
• Pelvic pain

Many early cervical cancers cause no symptoms, which is why screening is essential.

Esophageal SCC

• Progressive difficulty swallowing (dysphagia) — initially with solids, then liquids
• Painful swallowing (odynophagia)
• Unintentional weight loss
• Chest discomfort or substernal pain

Lung SCC

• Persistent cough, or a change in a longstanding cough
• Haemoptysis (coughing blood)
• Shortness of breath
• Chest pain or tightness
• Hoarseness (if tumor involves the recurrent laryngeal nerve)
• Recurrent or persistent chest infections

Anal SCC

• Anal bleeding (often confused with haemorrhoids — persistent or unexplained bleeding should be evaluated)
• Anal pain or pressure
• A palpable lump near the anus
• Change in bowel habits
• Feeling of incomplete bowel emptying

Vulvar and Penile SCC

• Persistent pruritus (itching) of the vulvar or penile skin
• A visible lump, wart-like growth, or ulcer
• Bleeding or unusual discharge
• Skin discolouration or thickening that doesn’t resolve
• Enlarged lymph nodes in the groin

When to seek evaluation: Any skin lesion that doesn’t heal, grows, or bleeds persistently; a new neck lump; persistent voice change or swallowing difficulty; abnormal vaginal bleeding; or persistent ano-genital symptoms should prompt medical assessment. These symptoms are not specific to SCC and most have other causes — but they warrant evaluation rather than observation.

How SCC Is Diagnosed — Biopsy, Pathology, and Biomarkers

Tissue biopsy is required to confirm the diagnosis of squamous cell carcinoma. Imaging and clinical examination can raise suspicion and guide staging but cannot replace histopathological confirmation. The type of biopsy depends entirely on the anatomical location and lesion characteristics.

Biopsy by Location

Pathological Features of SCC

Under the microscope, well-differentiated SCC typically shows:

• Malignant squamous cells with evidence of keratinisation (keratin pearls or individual cell keratinisation)
• Intercellular bridges between cells
• Nuclear atypia (enlarged, irregular nuclei)
• Invasive growth through the basement membrane

Poorly differentiated SCC may show minimal keratinisation, making definitive squamous identity less obvious — which is where immunohistochemistry becomes important.

Immunohistochemistry

Squamous differentiation markers help confirm the diagnosis and distinguish SCC from other cancer types when histology is equivocal:

• p40 (highly specific for squamous differentiation)
• p63 (squamous and other epithelia)
• High-molecular-weight cytokeratins (CK5/6)

No single marker alone establishes the diagnosis — interpretation is context-dependent.

Biomarker Testing

How SCC Is Staged

There is no single universal staging system for squamous cell carcinoma — staging is entirely site-specific, and using the wrong staging system for a given SCC would produce clinically meaningless information. Most systems use TNM (Tumor-Node-Metastasis) as a framework, but the specific criteria differ substantially between anatomical sites.

Why Staging Differs by Site

The anatomical structure of each organ determines what “local extension” means (T stage), which lymph nodes are regional (N stage), and what constitutes distant metastasis. A 2 cm tumor in one site may be T1; in another, it may be T2 or T3. This is why it is incorrect to speak of “Stage 2 SCC” without specifying where the tumor originated.

Site-Specific Staging Overview

Key practical point: When a patient is told they have “Stage X SCC,” the site of origin must always be specified for that staging to have any clinical meaning. Asking “what stage is my SCC?” without specifying the primary site cannot be meaningfully answered.

Treatment of Cutaneous SCC

Most localised cutaneous SCCs are effectively treated with surgical excision. The specific approach depends on tumor size, location, high-risk features, and available surgical expertise. Radiation, topical treatments, and systemic therapy have specific indications but are not first-line for most straightforward skin SCCs.

Surgical Excision

Standard excision with a defined clinical margin is the most common treatment for cutaneous SCC. The margin required depends on the tumor’s size, location, and risk classification — high-risk SCCs generally require wider margins. Excised tissue is sent for pathological margin assessment.

Mohs Micrographic Surgery

See Section 16 for detailed explanation. Mohs is particularly used for:

• High-risk or large SCCs
• Tumors on the face, ears, scalp, or other anatomically sensitive sites
• Recurrent SCCs
• SCCs with poorly defined clinical margins
• Selected immunosuppressed patients

Curettage and Electrodessication

A technique using a curette (scraping tool) and electrical current. Appropriate only for selected small, low-risk, superficial SCCs in non-critical locations. Not appropriate for high-risk SCCs.

Radiation Therapy

Used when surgery is not feasible or optimal:

• Patients who cannot tolerate surgery
• Specific anatomical locations where surgery would cause unacceptable functional or cosmetic damage
• Adjuvant treatment after surgery in selected high-risk cases (perineural invasion, close/positive margins, extensive nodal disease)
• Selected older patients with large tumors

Systemic Therapy for Advanced Cutaneous SCC

For unresectable, locally advanced, or metastatic cutaneous SCC:

• Cemiplimab (anti-PD-1 immunotherapy): Approved for advanced cutaneous SCC in multiple jurisdictions
• Pembrolizumab: Also approved in selected settings
• Chemotherapy: Used when immunotherapy is contraindicated or not available; less commonly first-line in the era of checkpoint inhibitors for advanced disease
• Clinical trials: An important consideration for patients with refractory or recurrent advanced cutaneous SCC

Mohs Micrographic Surgery

Mohs micrographic surgery is a specialised surgical technique for skin cancer removal in which tissue is excised in carefully mapped layers, with each layer immediately examined microscopically by the surgeon before proceeding. This allows complete margin control while maximising preservation of normal tissue.

How Mohs Differs from Standard Excision

In standard excision, a margin is taken and the tissue is sent to an external pathology laboratory — results return hours to days later. In Mohs surgery, the surgeon acts as surgeon and pathologist simultaneously, processing and examining tissue sections during the procedure. If cancer cells are found at a margin, more tissue is removed in the precise area where residual cancer remains, rather than removing a wider uniform margin in all directions.

When Mohs Is Particularly Useful

What Mohs Does Not Guarantee

Mohs surgery achieves complete margin clearance at the time of procedure, but:

• It does not prevent future new primary SCCs
• It does not eliminate the risk of distant spread if the tumor already had vascular or perineural involvement
• Lymph-node assessment may be separately required for high-risk tumors

Head and Neck SCC Treatment

Head and neck SCC treatment is complex, requiring multidisciplinary planning. The choice between surgery-first and radiation-first approaches depends on the specific tumor site, stage, HPV status, surgical resectability, and goals of care — particularly functional preservation of speech and swallowing.

Treatment Approaches by Subsite

Oral cavity SCC: Surgery is generally the primary treatment for resectable tumors. Postoperative radiation (with or without chemotherapy) is added in high-risk cases (positive/close margins, perineural invasion, lymphovascular invasion, positive lymph nodes).

Oropharyngeal SCC: Both surgery (increasingly performed via transoral robotic surgery, TORS) and primary chemoradiation are used for localised disease — the choice depends on anatomy, stage, and local expertise. Active research in HPV-positive disease is examining whether de-escalation of treatment intensity can maintain outcomes while reducing side effects.

Laryngeal SCC: Voice and swallowing preservation are key considerations. Options include radiation alone (for selected early-stage), concurrent chemoradiation (for organ-preservation intent in locally advanced disease), or surgery.

Key Agents in Head and Neck SCC

• Cisplatin: Standard concurrent chemotherapy agent with radiation in locally advanced head and neck SCC
• Cetuximab (anti-EGFR): An option when cisplatin is contraindicated
• Pembrolizumab: Approved in the first-line setting for recurrent/metastatic head and neck SCC with appropriate PD-L1 expression — verify current 2026 indication details
• Nivolumab: Approved in platinum-refractory recurrent/metastatic head and neck SCC

Treatment of Cervical, Esophageal, Lung, and Anal SCC

Cervical SCC Treatment

Chemoradiation (external beam radiotherapy plus concurrent cisplatin) followed by brachytherapy is the standard of care for most locally advanced cervical SCC. Surgery (radical hysterectomy with lymph-node dissection) is an option for selected early-stage disease in patients who are appropriate surgical candidates. For recurrent or metastatic disease, systemic therapy including chemotherapy combinations and immunotherapy (pembrolizumab is approved for certain settings) is used.

Esophageal SCC Treatment

Esophageal SCC treatment is stage-dependent. Very early lesions may be amenable to endoscopic resection. For resectable localised disease, surgery (esophagectomy) ± neoadjuvant chemoradiation is the main approach. For locally advanced disease, definitive chemoradiation may be used. And for metastatic disease, systemic therapy including chemotherapy and immunotherapy (nivolumab has approval in certain esophageal SCC settings) is used.

Lung SCC Treatment

Lung SCC treatment follows the same framework as other NSCLC by stage. Early-stage disease is treated surgically ± adjuvant therapy. Locally advanced disease typically receives concurrent chemoradiation. Advanced disease is treated with immunotherapy (pembrolizumab-based regimens for appropriate PD-L1 expression) and chemotherapy. Targeted therapy is less commonly applicable in lung SCC than in lung adenocarcinoma, but molecular testing should still be performed.

Anal SCC Treatment

Concurrent chemoradiation (5-FU/mitomycin-C or 5-FU/cisplatin with radiation) is the established primary treatment for most localised anal SCC and can achieve sustained disease control while preserving sphincter function. Abdominoperineal resection is reserved for persistent or recurrent disease after chemoradiation. Immunotherapy (pembrolizumab) has regulatory approval in certain advanced anal SCC settings.

Radiation Therapy in SCC

Radiation therapy plays a major role across multiple SCC types — as primary treatment, as a component of chemoradiation, or as adjuvant treatment after surgery — with specific indications varying by tumor site, stage, and treatment goals.

Roles of Radiation in SCC by Context

Modern Radiation Techniques

• IMRT (Intensity-Modulated Radiation Therapy): Shapes dose to spare nearby healthy structures; standard in head and neck SCC
• IGRT (Image-Guided Radiation Therapy): Real-time imaging during treatment to account for patient positioning
• Stereotactic Body Radiation Therapy (SBRT): High doses per fraction; used in selected lung SCC, reirradiation, and other settings
• Brachytherapy: Internal radiation; essential component of cervical cancer treatment

Chemotherapy in SCC

Chemotherapy in SCC is used in combination with radiation (chemoradiation), before surgery (neoadjuvant), after surgery (adjuvant), or for palliative treatment in advanced disease. The specific regimen is entirely site-dependent — there is no single SCC chemotherapy protocol.

Common Chemotherapy Agents by Site

Immunotherapy in SCC

Immune checkpoint inhibitors — particularly anti-PD-1 and anti-PD-L1 antibodies — now have established roles in several advanced SCC types. However, specific approved indications differ by tumor site, PD-L1 status, and prior treatment history. Immunotherapy is not appropriate for every SCC patient, and eligibility should be determined by a medical oncologist familiar with the relevant site-specific evidence.

Approved Immunotherapy Indications by Site (Verify Current 2026 Status)

What Patients Need to Know About Immunotherapy

• Not every SCC patient is eligible — biomarker testing (PD-L1, MSI status) and clinical factors influence eligibility
• Immunotherapy can cause immune-related adverse events — inflammation of the lungs, liver, colon, endocrine glands, and other organs — requiring prompt recognition and management
• Response patterns differ from chemotherapy — some patients have prolonged durable responses; others do not respond
• Autoimmune conditions and organ transplant history may affect eligibility

Advanced, Metastatic, and Recurrent SCC

Advanced, metastatic, or recurrent SCC requires reassessment of the anatomical site, prior treatments, current molecular/biomarker profile, and patient fitness before a new treatment plan is developed — repeating the original treatment is not automatically appropriate.

Patterns of Spread

Common patterns of regional and distant spread differ by site:

• Cutaneous SCC: Regional lymph nodes (parotid, cervical, inguinal depending on location); rarely distant spread — but when it occurs, lungs and liver are typical sites
• Head and neck SCC: Cervical lymph nodes (commonly involved at presentation); lungs, bone, liver in distant metastasis
• Cervical SCC: Para-aortic lymph nodes, lungs, liver, bone
• Lung SCC: Bone, brain, liver, adrenal glands, contralateral lung
• Anal SCC: Liver, lungs, distant lymph nodes

Recurrent SCC Management Principles

• Confirm recurrence with imaging and biopsy where feasible (scar tissue vs recurrence cannot always be distinguished clinically)
• Assess whether prior radiation field limits re-irradiation
• Check whether biomarkers have changed (tumors can evolve between initial diagnosis and recurrence)
• Consider clinical trial eligibility — particularly for higher-grade or refractory disease

Prognosis — What Affects Outcomes

Prognosis in SCC is profoundly site-dependent and within each site is influenced by stage, tumor grade, lymph-node involvement, HPV status (where relevant), molecular features, and treatment response. No single survival figure can meaningfully represent “SCC” as a whole.

Factors That Generally Influence Prognosis

Favourable indicators typically include:

• Early stage at diagnosis
• Complete surgical resection with clear margins
• HPV-positive oropharyngeal SCC (generally more favourable than HPV-negative)
• Small tumor size
• No lymph-node involvement
• Good response to systemic treatment

Less favourable indicators typically include:

• Metastatic disease at presentation
• High-grade/poorly differentiated histology
• Perineural or lymphovascular invasion (cutaneous SCC)
• Positive lymph nodes
• Recurrence after treatment
• Immunosuppression (cutaneous SCC)

Why Site-Specific Survival Statistics Matter

A patient diagnosed with cutaneous SCC of the hand has a fundamentally different statistical outlook from a patient diagnosed with advanced esophageal SCC. Publishing a combined “SCC survival rate” would be as misleading as combining survival statistics for all lung diseases. Patients should receive site-specific prognostic guidance from their oncologist, who can assess individual factors rather than quoting population statistics.

Prevention and Risk Reduction

SCC prevention strategies are site-specific — UV protection reduces skin SCC risk, HPV vaccination reduces HPV-associated SCC risk, and tobacco cessation reduces the risk of multiple mucosal SCC types. No single prevention strategy addresses all forms of SCC.

Skin SCC Prevention

• Use broad-spectrum sunscreen (SPF 30+) consistently on sun-exposed skin
• Avoid deliberate tanning, including sunbeds/tanning beds
• Wear protective clothing, hats, and eyewear
• Seek shade during peak sun hours
• For high-risk patients (organ transplant recipients, prior SCC, extensive actinic keratoses): regular dermatological review; discuss field treatment for actinic keratoses

HPV-Related SCC Prevention

• HPV vaccination — most effective when administered before HPV exposure (pre-sexual debut), but has benefit in some adult populations too; consult current national vaccination guidance
• Cervical screening (cytology and/or HPV co-testing) per national guidelines — detects precancerous changes before invasive cancer develops
• Appropriate safe practices

Tobacco and Alcohol-Related SCC Prevention

• Smoking cessation reduces the risk of multiple SCC types (head and neck, lung, oesophageal)
• Cessation support (nicotine replacement, pharmacotherapy, counselling) is effective and should be accessed
• Limiting alcohol, particularly in combination with tobacco use, reduces head and neck cancer risk

SCC Treatment Cost in India

There is no single “SCC treatment cost.” Costs vary dramatically depending on which organ the SCC originates from, the treatment required, disease stage, and hospital. A cutaneous SCC requiring Mohs surgery is a fundamentally different cost profile from metastatic lung SCC requiring immunotherapy.

Approximate Cost Ranges by Treatment Category (International Patients)

These are orientation ranges only. International patient pricing at major Indian hospitals is typically higher than domestic pricing. Request a formal estimate based on your actual diagnosis and treatment plan.

Cutaneous SCC:

• Simple excision (localised, low-risk): approximately USD 500–2,000 (procedure + pathology)
• Mohs micrographic surgery: approximately USD 1,500–5,000+ depending on complexity
• Radiation therapy (for unresectable cutaneous SCC): approximately USD 4,000–10,000 for a full course
• Immunotherapy (cemiplimab/pembrolizumab): several hundred to over USD 1,000 per infusion — treatment continues over months; total cost is substantial

Head and Neck SCC:

• Major head and neck surgery (neck dissection, laryngectomy, etc.): approximately USD 8,000–20,000+
• Concurrent chemoradiation: approximately USD 8,000–15,000+
• Immunotherapy in metastatic setting: ongoing cost per infusion

Cervical SCC:

• Radical hysterectomy (early stage): approximately USD 5,000–12,000
• Concurrent chemoradiation + brachytherapy: approximately USD 8,000–18,000+

Esophageal SCC:

• Esophagectomy: approximately USD 12,000–22,000+ (major surgery with ICU)
• Chemoradiation: approximately USD 8,000–15,000+

Lung SCC:

• Surgery (lobectomy): approximately USD 8,000–18,000
• Immunotherapy-based systemic treatment: cost is ongoing per treatment cycle

Anal SCC:

• Chemoradiation: approximately USD 6,000–14,000

Verification note: The ranges above are approximate guidance only, reflecting available Indian hospital pricing information for international patients. Significant variation exists between hospitals and based on disease complexity. A hospital-specific estimate based on reviewing your actual imaging and pathology is the only reliable figure.

Choosing the Right SCC Treatment Centre

The appropriate treatment centre for SCC depends entirely on the anatomical site of the cancer. A centre specialising in Mohs surgery for skin cancer is not the same as a centre equipped for concurrent chemoradiation and head and neck oncology. Matching the patient’s SCC type to the right specialist team matters more than any general hospital ranking.

Capabilities by SCC Type

International Patient Coordination

For patients considering treatment in India, Shifam Health can help:

1. Identifying the anatomical SCC type from existing pathology reports
2. Coordinating medical record review with the appropriate specialist team
3. Facilitating a multidisciplinary treatment recommendation
4. Preparing a cost estimate based on the planned treatment
5. Medical visa documentation assistance
6. Travel and accommodation planning
7. Post-treatment follow-up coordination

Connect With Shifam Health for SCC Treatment Coordination

Whether your SCC is a localised skin tumor or a more complex cancer requiring multidisciplinary treatment, the first step is ensuring your pathology and imaging are reviewed by the appropriate specialist team.

Shifam Health can coordinate:

• Review of biopsy reports and imaging by the relevant site-specific specialist team
• Multidisciplinary treatment recommendation
• Hospital-specific cost estimates
• Medical visa documentation assistance (see our Medical Visa guide)
• Travel, accommodation, and arrival coordination
• Post-treatment follow-up communication

[Share Your Pathology and Imaging for a Free Specialist Review →]

[Speak With Our International Patient Team →]

Frequently Asked Questions

Relatable Reads:

• Cancer Treatment in India
• Cancer Treatment Cost in India
• Cervical Cancer Treatment Cost in India
• Lung Cancer Treatment Cost India
• Radiation Therapy in India
• Indian Medical Visa Guide
• Emergency Medical Visa India
• Medical Tourism in India: Complete Guide
• HPV Vaccine India